A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study

被引：0
|
作者：
Daniele, Bruno
Di Maio, Massimo
Gallo, Ciro
Gasbarrini, Antonio
Carteni, Giacomo
Di Costanzo, Giovan Giuseppe
Craxi, Antonio
Cabibbo, Giuseppe
Bolondi, Luigi
Granito, Alessandro
Missale, Gabriele
Frassoldati, Antonio
Angelico, Mario
Roselli, Mario
Daniele, Gennaro
Perrone, Francesco
机构：
[1] G Rummo Hosp, Benevento, Italy
[2] Natl Canc Inst, Clin Trials Unit, Naples, Italy
[3] Univ Naples 2, Naples, Italy
[4] Policlin Univ Agostino Gemelli, Rome, Italy
[5] Azienda Osped Rilievo Nazl A Cardarelli, Naples, Italy
[6] Azienda Osped Univ, Policlin Paolo Giaccone, Palermo, Italy
[7] Azienda Osped Univ Policlin St Orsola Malpighi, Bologna, Italy
[8] Azienda Osped Univ Parma, Parma, Italy
[9] Az Osped Univ Arcispedale St Anna Ferrara, Ferrara, Italy
[10] Azienda Osped Univ Policlin Tor Vergata, Rome, Italy
[11] Natl Canc Inst, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4151
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopheri J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] A randomized phase II study comparing trabectedin (T) and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS).
    Takahashi, Shunji
    Araki, Nobuhito
    Sugiura, Hideshi
    Ueda, Takafumi
    Takahashi, Mitsuru
    Morioka, Hideo
    Yonemoto, Tsukasa
    Hiraga, Hiroaki
    Hiruma, Toru
    Kunisada, Toshiyuki
    Matsumine, Akihiko
    Kawai, Akira
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Ma, Yuk Ting
    Peck-Radosavljevic, Markus
    Ross, Paul J.
    Graham, Janet Shirley
    Fartoux, Laetitia
    Deptala, Andrzej
    Wenz, Arne
    Hocke, Julia
    Loembe, Arsene-Bienvenu
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [34] PRELIMINARY PHARMACOKINETICS (PK) AND SAFETY COMPARISON OF CHILD-PUGH A (CPA) VS. CHILD-PUGH B (CPB) PATIENTS (PTS) ENROLLED IN A PHASE 2 STUDY IN HEPATOCELLULAR CARCINOMA (HCC)
    Gupta, N.
    Chiu, Y.
    Toh, H. C.
    Chen, P.
    Yong, W.
    McKee, M.
    Ricker, J. L.
    Carlson, D. M.
    Pradhan, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 237 - 237
  • [35] Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients (pts) with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.
    Ciuleanu, T.
    Samarzjia, M.
    Demidchik, Y.
    Beliakouski, V.
    Rancic, M.
    Bentsion, D. L.
    Orlov, S. V.
    Schaeffier, B. A.
    De Jager, R. L.
    Breitz, H. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
    Kang, Y-K.
    Kang, W. K.
    Di Bartolomeo, M.
    Chau, I.
    Yoon, H. H.
    Cascinu, S.
    Ryu, M-H.
    Kim, J. G.
    Lee, K-W.
    Oh, S. C.
    Takashima, A.
    Kryzhanivska, A.
    Chao, Y.
    Vladimirov, V.
    Evesque, L.
    Schenker, M.
    McGinn, A.
    Sankar, N.
    Wyrwicz, L.
    Boku, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] MULTICENTRE PHASE III TRIAL COMPARING VINFLUNINE (V) PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS 2ND LINE THERAPY AFTER A PLATINUM-CONTAINING REGIMEN, IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM (TCCU)
    von der Maase, H.
    James, N.
    Winquist, E.
    Karyakin, O.
    Jagiello-Gruszfeld, A.
    Lorenz, J.
    van Herpen, C.
    Delgado, F.
    Salhi, Y.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 202 - 202
  • [38] Final results of a randomized phase II study comparing trabectedin and best supportive care (BSC) in patients (pts) with translocation-related sarcomas (TRS)
    Kunisada, T.
    Takahashi, S.
    Araki, N.
    Sugiura, H.
    Ueda, T.
    Yonemoto, T.
    Takahashi, M.
    Morioka, H.
    Hiraga, H.
    Hiruma, T.
    Matsumine, A.
    Kawai, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S704 - S704
  • [39] Efficacy and safety of sorafenib as first-line therapy of patients (pts) with advanced Child-Pugh B Hepatocellular Carcinoma (HCC): A systematic review and meta-analysis
    McNamara, M.
    Slagter, A.
    Rigby, C.
    Lamarca, A.
    Valle, J.
    Hubner, R.
    Amir, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S446 - S446
  • [40] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
    Muszbeck, N.
    Vioix, H.
    Munir, U.
    Schiola, A.
    Valderrama, A.
    Teich, V
    VALUE IN HEALTH, 2010, 13 (03) : A36 - A36
12345